Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03093922 · ClinicalTrials.gov registry record · Phase 2

A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

A Phase 2 study of Urothelial Carcinoma and Locally Advanced, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
Phase 2
Development phase
32
Enrollment target
9
Study locations

NCT03093922 is a Phase 2 study of Urothelial Carcinoma and Locally Advanced that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 32 participants, below the 239-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (87% lower). The trial reports 9 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03093922, a Phase 2 study of Urothelial Carcinoma and Locally Advanced, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
32 participants
Enrollment target
9
Study locations

Study Summary

The purpose of this study is to compare any good and bad effects the study drug atezolizumab has on the cancer when combined with the standard chemotherapy drugs gemcitabine and cisplatin (or GC) in two different dosing schedules: chemotherapy (GC) before atezolizumab vs. GC after atezolizumab.

Conditions Studied

Urothelial Carcinoma Locally Advanced Unresectable

Interventions

  • DRUG Atezolizumab
  • DRUG Cisplatin
  • DRUG Gemcitabine

Study Locations (9)

New York

  • Memorial Sloan Kettering Commack (Limited Protocol Activities) - Commack
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale

New Jersey

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
  • Memorial Sloan Kettering Bergen - Montvale

Illinois

  • University of Chicago - Chicago

Ohio

  • Ohio State University - Columbus

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2017-03-22
Est. Completion 2026-03
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03093922

The ClinicalTrials.gov registry entry for NCT03093922 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (87% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Urothelial Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Atezolizumab is the first listed.

NCT03093922 reports 9 study locations spanning 4 distinct geographic areas - top geographies include New York, New Jersey, Illinois.

Frequently Asked Questions

What is clinical trial NCT03093922 about?

NCT03093922 is a clinical study titled "A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer". The purpose of this study is to compare any good and bad effects the study drug atezolizumab has on the cancer when combined with the standard chemotherapy drugs gemcitabine and cisplatin (or GC) in two different dosing schedules: chemotherapy (GC) before atezolizumab vs. GC after atezolizumab.

What is the current status of trial NCT03093922?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2017-03-22. Estimated completion is 2026-03.

What conditions does trial NCT03093922 study?

This clinical trial studies the following conditions: Urothelial Carcinoma, Locally Advanced, Unresectable.

What interventions are being tested in trial NCT03093922?

The interventions under investigation include: Atezolizumab (DRUG), Cisplatin (DRUG), Gemcitabine (DRUG).

Who is sponsoring clinical trial NCT03093922?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03093922 being conducted?

This trial has 9 study locations across Illinois, New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Urothelial Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Urothelial Carcinoma

All registered trials for this condition

Locally Advanced

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.